NeurAxis, Inc. (NRXS)
| Market Cap | 90.55M +443.2% |
| Revenue (ttm) | 4.28M +45.9% |
| Net Income | -8.07M |
| EPS | -0.82 |
| Shares Out | 11.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,068 |
| Open | 8.29 |
| Previous Close | 8.35 |
| Day's Range | 7.70 - 8.29 |
| 52-Week Range | 2.07 - 9.33 |
| Beta | 1.48 |
| Analysts | Strong Buy |
| Price Target | 13.00 (+65.18%) |
| Earnings Date | May 12, 2026 |
About NRXS
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation di... [Read more]
Financial Performance
In 2025, NeurAxis's revenue was $3.57 million, an increase of 32.89% compared to the previous year's $2.69 million. Losses were -$8.62 million, 1.92% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for NRXS stock is "Strong Buy" and the 12-month stock price target is $13.0.
News
NeurAxis Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 80% year-over-year to $1.6 million, with gross margin expanding to 86.4% and cash burn declining. Commercial focus is on deepening adoption in covered pediatric markets and expanding VA presence, while payer coverage and execution remain key growth drivers.
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
CARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic a...
NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ch...
NeurAxis Expands Payer Coverage with Four New Medical Policies
CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...
NeurAxis, Inc. Announces Preferred Stock Dividend
CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
Neuraxis price target raised to $13 from $8 at Craig-Hallum
Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on Neuraxis (NRXS) to $13 from $8 and keeps a Buy rating on the shares after Q1 results, which exceeded expectations…
NeurAxis Earnings Call Transcript: Q4 2025
Q4 2025 saw double-digit revenue growth and major milestones, including expanded payer coverage and a new CPT code. Gross margins remained strong despite product mix shifts, and liquidity improved with new capital raised. Execution focus and expanding policy coverage are expected to drive further growth.
Neuraxis reports Q4 revenue $968K vs. $761K last year
Reports Q4 net loss ($1.7M), up 18% vs. ($1.4M) in 4Q24. CEO Brian Carrico commented: “We believe NeurAxis (NRXS) has entered a new phase of its growth trajectory. With the…
NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
NeurAxis Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
Significant milestones include a new Category I CPT code, expanded insurance coverage, and strong clinical data supporting a non-drug device for pediatric and adult GI disorders. Financials show solid margins and a clear path to profitability, with a focus on scaling coverage and revenue.
Neuraxis announces Category I CPT code for PENFS now in effect
NeurAxis (NRXS) announced that the Category I CPT code for Percutaneous Electrical Nerve Field Stimulation, PENFS, is now in effect, completing a successful commercial milestone for the Company. The a...
Neuraxis management to meet virtually with Craig-Hallum
Virtual Meeting to be held on January 6 hosted by Craig-Hallum.
Neuraxis management to meet virtually with Craig-Hallum
Virtual Meeting to be held on December 30 hosted by Craig-Hallum.
Neuraxis price target raised to $8 from $7 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Neuraxis (NRXS) to $8 from $7 and keeps a Buy rating on the shares after the company announced that they have been included…
Neuraxis achieves medical coverage policy milestone for PENFS
NeurAxis (NRXS) announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation, PENFS. The coverage spans multiple states an...
Neuraxis secures VA Federal Supply Schedule contract
NeurAxis (NRXS) has been awarded a Veterans Affairs Federal Supply Schedule contract, effective December 1, 2025. The first product listed on the FSS is the IB-Stim, a drug-free treatment for…
Neuraxis announces new medical policy coverage in Michigan
NeurAxis (NRXS) announced new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation, PENFS, representing approximately 566,000 total covered lives, in Michigan. With this additio...
NeurAxis Earnings Call Transcript: Q3 2025
Q3 2025 saw 22% revenue growth and the fifth straight quarter of double-digit gains, driven by IB-STIM adoption and FDA label expansion. The new Category 1 CPT code effective in 2026 is expected to accelerate adoption and improve margins, with cash runway into H2 2026.
Neuraxis reports Q3 revenue $811k vs $667k last year
Brian Carrico, Chief Executive Officer of NeurAxis (NRXS), commented: “We remain highly optimistic as we lay the foundation for what we expect will be a major scaling phase in 2026.
NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues
Conference call will be held today, Tuesday, November 11 at 9:00 am ET Conference call will be held today, Tuesday, November 11 at 9:00 am ET
Neuraxis received FDA 510k clearance for PENFS technology
NeurAxis (NRXS) announced that it has received FDA 510(k) clearance for its proprietary percutaneous electrical nerve field stimulation, PENFS, technology for the treatment of functional abdominal pai...
NeurAxis Transcript: Lytham Partners Fall 2025 Investor Conference
IB-Stim is the first FDA-cleared treatment for pediatric functional abdominal pain and dyspepsia, addressing a major unmet need. With new NASPGHAN guideline support, a Category I CPT code effective January 2026, and expanding insurance coverage, significant market penetration and revenue growth are expected.
NeurAxis Earnings Call Transcript: Q2 2025
Q2 2025 saw 46% revenue growth, major milestones including FDA indication expansion, and assignment of a favorable Category I CPT code. Gross margin declined due to discounting, but profitability and cash flow breakeven remain on track as insurance coverage expands and new policies take effect.
Neuraxis reports Q2 EPS (22c) vs. (42c) last year
Reports Q2 revenue $894,000 vs. $612,000 last year. Brian Carrico, CEO of NeurAxis (NRXS) commented “We remain highly encouraged by the Company’s trajectory, with strong revenue growth anticipated in ...
Neuraxis management to meet with Craig-Hallum
Meeting to be held in Minneapolis on June 26 hosted by Craig-Hallum.